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Background/aim: To investigate the effect of transcorneal electrical stimulation (TES) therapy in patients with retinitis pigmentosa
(RP).
Materials and methods: We performed TES therapy in 21 patients with RP in 12 sessions with 1-week intervals. The following
parameters obtained before and after the TES therapy were compared statistically; the best corrected visual acuity (BCVA, logMAR),
Ishihara color vision level, multifocal electroretinography (mf-ERG) response, automated visual field (VF) outcome, and the 25-item
low vision quality-of-life (LVQOL) questionnaire points.
Results: The mean age of patients (6 females; 15 males) was 31.67 ± 9.80 years (20–50 years). While increases in BCVA level, color vision
level, mf-ERG response in p1 amplitude of ring 1, and LVQOL questionnaire points were statistically significant, changes in VF test and
other mf-ERG responses were not. Twenty of the patients (95.24%) stated that they were satisfied with the TES therapy. No considerable
side effect was observed in any patient due to the therapy.
Conclusion: The TES therapy may be an effective and safe treatment modality in slowing the RP progression, especially in the early
stages of the disease. Longer-term follow-ups in larger patient populations are warranted.
Key words: Multifocal electroretinography, retinitis pigmentosa, tes therapy, transcorneal electrical stimulation, visual field

1. Introduction
Retinitis pigmentosa (RP) is a genetic retinal disorder
which results from progressive degeneration of retinal
photoreceptor layer and adjacent tissues [1]. In the early
stages of disorder, patients with RP complain about night
blindness only. As the disease progresses, the patients
complain of narrowing of the visual field (VF) because of
loss of the rod photoreceptor cells in the peripheral retina,
and decreased vision in dim environments. It eventually
leads to permanent blindness as the central vision is also
affected. Numerous studies including stem cell and gene
therapies, are currently performed under investigation for
the treatment of RP, but there is no definitive treatment
yet. There is not even a treatment method that ceased the
vision loss in these patients destined to blindness.
Transcorneal electrical stimulation (TES) therapy is a
newer treatment method that seems applicable to retinal
diseases that have no cure in the current. TES therapy has
been shown to slow the progression of RP and also leads

to clinical improvement thanks to neuroprotective effects
on the retina [2,3]. It is thought that TES application affects
the remaining healthy retinal cells (dormant cells) [3].
There are also some case reports in the literature about the
positive effects of TES therapy in some ocular pathologies
with no definitive treatment [4–6].
We aimed to investigate the effects of TES therapy in
RP patients in the early stages of disease in this study.
2. Materials and methods
During May 2017 to June 2018 period, the files of 21 RP
patients who underwent TES therapy were analyzed. All
participants had night vision problems associated with
classical fundus findings including pallor optic disc,
narrowed vascular tree, and bone-spicule pigmentation.
2.1. Inclusion criteria
1. Patients who had the typical clinical and
electrophysiological findings of RP.
2. Age ≥20 years and ≤50 years
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3. BCVA ≥ 0.1 (Snellen chart).
4. Patients who had TES therapy regularly for 12
sessions with a 1-week interval.
5. Patients who signed informed consent documents
with sufficient understanding after receiving an explanation
for the responsibility of TES therapies.
6. Patients with complete information on objective and
subjective variables in their files.
2.2. Exclusion criteria
1. Patients who had any systemic disease.
2. Patients who had another anterior or posterior
segment pathology
3. Patients who had an ocular trauma, or an eye
operation except for cataract surgery.
4. Age <20 years or >50 years
5. BCVA < 0.1 (Snellen chart).
6. Patients who had advanced RP findings (severe optic
disc atrophy, bone spicules inside the arcades, or macular
pathology) according to Smith et al.’s grading clinical score
for RP [7].
7. Patients who had the therapies at irregular intervals
or incompletely.
8. Patients who do not have a written consent form in
their file.
We performed TES therapy in RP patients with
ocuvision system (CE approved, GmbH, Reutlingen,
Germany) consisting of stimulating device (Ocustim),
application spectacle (Ocuspex), and electrode (OcuEl)
as described previously [2,3,8]. While an ocular electrode
was placed on the cornea, two skin electrodes were placed
on temple area bilaterally. After determining the value of
electrical phosphene threshold (EPT), 12 sessions of TES
therapy were performed on the patients with an interval
of one week with the following parameters; 200% EPT,
200–400 μA power, 20 Hz frequency, 2 msec biphasic and
30 min duration.
All patients underwent a detailed ophthalmic
examination before starting TES therapy and after the last
TES therapy. The following parameters were compared 1
week before starting therapy and 1 week after all therapy has
been completed; the BCVA (Snellen chart), Ishihara color
vision level (the number of color plates reads correctly),
multifocal electroretinography (mf-ERG; RetiScan
3.22.0.1; Roland Instruments, Wiesbaden, Germany)
p1 wave amplitudes of ring 1, mean deviation (MD) in
automated VF (24-2 SITA-SAP, Humphrey Field Analyzer
II, Carl Zeiss Meditec, Inc., Dublin, CA, USA), the low
vision quality-of-life (LVQOL) questionnaire points [9].
This questionnaire has 25 items, 11 subscales including
overall activities, difficulty with near and distance vision
activities, limitations in social functioning, dependency
on others, mental health symptoms, driving difficulties,
limitations with peripheral and color vision, ocular pain,
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and an additional subscale for general health. It has been
created to measure the vision targeted health status for
patients with chronic eye diseases causing low vision
[9]. The mf-ERG responses of the patients with RP were
recorded using special electrodes and a standard protocol
as explained in detail previously [10]. The mf-ERG stimuli
location and anatomical areas corresponded as follows:
Ring 1, central hexagon overlying the fovea; Ring 2, the
parafoveal area; Ring 3, the perifoveal area; Rings 4 and
5, the far peripheral retina. Measurements of rings 4 and
5 were not evaluated because they do not correspond to
either fovea or peri/parafoveal area.
All ophthalmic examinations and LVQOL questionnaire
were performed by the same ophthalmologist (MND), and
all procedures were also performed under his supervision.
Written informed consent was obtained from all individual
participants, and all procedures were conducted according
to the Declaration of Helsinki. This study was approved by
the Review Board of Selçuk University Faculty of Medicine
(2020/456).
2.3. Statistical analysis
For all analyses, the IBM-SPSS version 21.0 was used. The
variables were described as mean ± standard deviation
(SD). The effectiveness of TES therapy was evaluated by
testing the mean differences against zero. For each numeric
variable, mean differences were calculated by subtracting
before TES therapy measurements from after TES therapy
measurements. For statistical analysis, BCVA obtained
with Snellen chart was converted to logMAR (logarithm of
the minimum angle of resolution). Normality assumption
was checked by Shapiro-Wilk’s test. Normally distributed
differences were tested with one-sample t-test while
nonnormally distributed differences were tested with
one-sample Wilcoxon signed-rank test. Furthermore,
categorical variables were reported using frequencies and
percentages. A value of p < 0.05 was considered statistically
significant.
3. Results
A total of 42 eyes of 21 patients with RP were included in
the study. The mean age of patients (6 females; 15 males)
was 31.67 ± 9.80 years (20–50 years). After the TES therapy
statistically significant changes were determined in all
parameters except improvements in VF test and mf-ERG
responses other than p1 amplitude (Table 1, 2, and Figure).
All patients except one (95.24%) stated that they were
satisfied with the TES therapy. The procedures were well
tolerated by all participants. Trivial symptoms such as
foreign body sensation, burning, and itching were observed
in only 3 (14.29%) patients. All symptoms were transient
and no considerable side effect and/or discomfort caused
to cease the therapy in any patient.
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Table 1. Changes in the objective and subjective parameters before and after transcorneal electrical stimulation therapy.
The mean ± standard deviation

P-value

Before TES therapy

After TES therapy

Best corrected visual acuity (LogMAR)

0.40 ± 0.31

0.26 ± 0.25

<0.001

Ishihara color vision level (plates)

12.48 ± 9.15

14.17 ± 8.27

<0.001

Mean deviation level in the automated visual field (dB)

–24.81 ± 6.68

–24.64 ± 6.83

0.31

Low vision quality-of-life questionnaire (points)

75.71 ± 17.11

88.90 ± 16.03

<0.001

Mean central foveal thickness (µm)

266.10 ± 50.95

265.95 ± 49.10

0.805

Table 2. Multifocal electroretinography responses of participants before and after TES therapy.
The mean ± standard deviation

P-value

Before TES therapy

After TES therapy

p1 amplitude of ring 1 (nv/deg2)

38.32 ± 20.22

48.23 ± 22.00

<0.001

p1 implicit time of ring 1 (ms)

43.20 ± 10.81

39.89 ± 10.60

0.111

p1 amplitude of ring 2 (nv/deg )

12.56 ± 4.08

12.99 ± 4.46

0.231

p1 implicit time of ring 2 (ms)

44.38 ± 11.29

41.48 ± 10.38

0.109

p1 amplitude of ring 3 (nv/deg )

6.54 ± 3.46

7.18 ± 3.95

0.159

p1 implicit time of ring 3 (ms)

42.72 ± 10.04

41.26 ± 10.63

0.129

2

2

4. Discussion
Although many different therapies have been applied to
the treatment of RP, there is no definitive treatment of the
disease yet [1,11–13]. This study showed that TES therapy
provided positive objective and subjective outcomes on
patients with RP. Especially, improvement in the LVQOL
questionnaire and the high satisfaction rate were very
gratifying and promising.
Morimoto et al. have shown that TES has a
neuroprotective effect by some experimental studies
[14–17]. Firstly, in 2002, Morimoto et al. [14] discovered
that optic nerve stimulation with electricity increased the
axotomized retinal ganglion cells (RGCs) survive. Then,
the same authors indicated that TES provides to survive
the axotomized RGCs by increasing IGF-1 levels [15].
Afterward, they investigated the TES effects in different
gene models for RP, and they demonstrated that TES
enabled photoreceptors to survive and preserved retinal
function in RCS rats and in rhodopsin P347L transgenic
rabbits [16,17]. Ni et al. [18] determined an upregulation
of B-cell lymphoma 2 (Bcl-2), ciliary nerve trophic factor
(CNTF), and brain-derived neurotrophic factor BDNF
and a downregulation of Bcl-2 associated x protein (Bax)
in the rats with light-induced photoreceptor degeneration.
The authors also found that Bcl-2 and CNTF were
selectively upregulated in Müller cells. Although the exact

mechanism of the TES has not been identified, it is thought
that the protective effects of therapy can be related with
upregulation of some neurotrophic factors, or vasodilatory,
antiapoptotic, antiglutamate, and antiinflammatory
mechanisms [19,20].
The safety and the feasibility of TES therapy in patients
with various ocular disorders such as RP, glaucoma,
amblyopia, homonymous VF loss, and normal individuals
were first investigated by Gekeler et al. [8]. They found that
the TES therapy using DTL electrodes was safe, fast, and
reliable.
There are four clinical studies evaluating the effects of
TES therapy [2,3,21,22], and there is one study investigating
the effects of transdermal electrical stimulation (TdES)
[23] on RP patients in the literature. The efficacy and the
safety of TES therapy in RP patients were first investigated
by Schatz et al. with a prospective, randomized and shamcontrolled clinical trial [2]. They performed TES therapy
using DTL electrodes to 24 RP patients for 30 min for 6
consecutive weeks with a one-week interval. They divided
patients into 3 groups: sham, 66%, or 150% of individual
EPT. They determined statistically significant improvement
in the VF and scotopic b-wave amplitude in 150% group,
whereas no change was observed in 66% group. They
reported foreign body sensation in only 2 (8.33%) patients
as an adverse event as in our study. Afterward, the same
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Figure. Multifocal electroretinography response of a patient with retinitis pigmentosa before and after TES therapy.

authors designed a clinical trial with a larger and over longer
period of time [3]. They performed the TES therapy on 52
RP patients for 30 min per week for 52 consecutive weeks.
They divided patients into 3 groups: sham, 150%, or 200%
of individual EPT. They found a significant improvement of
cone function (light-adapted single flash b-wave amplitude)
in both of the 150% and 200% EPT groups, and a significant
improvement of rode function (scotopic b-wave amplitude)
in 200% EPT group compared to the sham group.
We set the EPT value in our study as 200% in the light
of these studies. We selected the RP patients who had early
stages according to Smith et al.’s grading system considering
4 criteria for RP staging; lens status, optic disc appearance,
the extent of bone spicule pigmentation and presence of
macular pathology, developed in 2013 [7]. We included the
patients who had BCVA of more than 0.1. We thought that
these patients at this stage and BCVA level could have more
dormant cells to be activated and respond psychophysical
tests affirmatively.
Schatz et al. [2] performed TES therapy under the
supervision of an investigator and an assisting nurse by
using DTL electrodes in their first study, whereas it was
performed at home conditions by patients and/or relatives
themselves by using ocuvision system in their second
study [3]. They declared that the OkuStim devices allow
application of TES therapy by the patients themselves at
home, these devices can be detected ineffective electrode
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positions, and they did not report any conspicuity in
patients’ files pointing to mal- or dysfunction. In our study,
the same ophthalmologist performed the procedure in each
TES therapy and he has never left any patient alone and he
continuously confirmed the contact between the electrode
and the cornea. According to our observations; in the case of
absolute interruption status, the device stops automatically,
whereas the device can continue to run even if the contact
between the electrode and the cornea decreases. Therefore,
we do not find it appropriate to implement this therapy at
home conditions.
Wagner et al. [21] reported a study investigating the
safety and efficacy of TES treatment. They performed TES
to 14 RP patients weekly for 30 min for 6 months under
the supervision with 150% individual phosphene threshold.
The authors also observed the participants for a further 6
months without any treatment. They did not detect any
significant changes in the treatment group in terms of
the visual acuity, microperimetry, Goldmann VF, optical
coherence tomography and fundus autofluorescence
outcomes compared to the control group. They also reported
transient and spontaneous resolving foreign body sensation
in 2 participants (14.28%), and discomfort underneath the
skin electrode in 1 participant (7.14%) as the adverse events
of TES therapy [21].
Kahraman and Oner [22] recently reported a
prospective controlled study evaluating the safety and
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efficacy of TES treatment in RP patients. They compared
BCVA, VF, and mfERG findings of 101 RP patients who
underwent TES treatment 30 min once a week for 8
consecutive weeks and 100 RP patients who were enrolled
as control. They determined a statistically significant but
transient improvements in the treatment group. Since our
study had a short follow-up time period, we may encounter
such a negative result in the future. They did not observe
any serious ocular side effects related to the TES therapy as
in our study [22].
Miura et al. [23] evaluated the safety and efficacy of
TdES therapy with skin electrodes in 20 eyes of 10 patients
with RP. They performed the TdES 6 times at 2-week
intervals with the following parameters; 1.0 mA power, 20
Hz frequency, 10 msec biphasic, and 30 min. They observed
a statistically significant improvement in the mean BCVA
level, and MD of the 10.2 Humphrey VF. No adverse events
related to TdES were reported [23].
Our study results seem to be familiar to studies reported
by Schatz et al. [2,3] and Kahraman and Oner [22], whereas
it differed from Wagner et al’s study [21], considering
the improvements in BCVA as well as color vision, p1 in
mfERG and LVQOL. The fact that the number of patients in
Wagner et al’s study was limited, applied EPT value was low,
the mean age of patients was high (47.64 ± 18.76 years), and
5 (35.71%) of 14 participants had mild epiretinal membrane
and 1 patient had staphyloma. In contrast to their study, we
have achieved better objective and subjective improvements
in RP patients.
Increased color vision, visual acuity, and p1 amplitude
in mfERG suggest that TES therapy has positive effects on
cone photoreceptors. We think that the more successful
outcomes can be obtained by performing the TES therapy at
an earlier stage of the disease. Our participants, compared to
patients in other studies, might have more dormant cells. In

our study, patients with BCVA lower than 0.1 level (Snellen)
and severe RP findings were excluded from the study. Initial
BCVAs of patients were better, and they were younger
than the above-mentioned studies. Therefore, starting the
therapy in the early stages with relatively preserved macula
would result in more benefit from TES therapy. Wang et al.
[24] also demonstrated that glucose replacement restored
the dormant cone electrophysiology in a pig model of
autosomal-dominant RP.
There are some limitations in our study. The number
of our participants was limited as the patients who had the
opportunity to apply this therapy in 12 sessions with 1-week
intervals were included in the study. Our study also has a
retrospective design and short follow-up time, and has not a
control or sham group. Taking the BCVA from the patients
with limited visual acuity such as RP would be better by
using ETDRS chart which we do not have instead of Snellen
chart. We were also able to define the molecular genetic
basis in some of the participants only; therefore, we could
not include this variable in the study. On the other hand,
improvements in the LVQOL points together with safety of
the procedures favor the use of TES therapy in RP patients.
The device used during the TES therapy also has some
limitations such as the cost of the device and the kit being
high, the absence of metal frames of different sizes for
patients with different anatomy.
In conclusion; we found that TES therapy was effective,
safe, and well-tolerated in patients with RP. Further studies
with a larger number of patients exploring the optimum
TES therapy parameters such as treatment dose, duration,
session, EPT value, and the patient group that will benefit
most from the treatment, are needed. We should continue
to follow up the patients who underwent TES therapy in
the long-term period in order to compare the long-term
outcomes, too.
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